Skip to main content

Table 4 AHP results- normalized matrix

From: Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

MCDA criteria Indication uniqueness Disease rarity Disease severity Adv.tech. Manufacturing technology Therapeutic alternative Sci. evid. Clin.eff Benefits from use of medicine (safety aspects) Cost effectiveness analysis Budget impact analysis Therapy cost HTA recommendations issued elsewhere Rationalization analysis Weight
Indication uniqueness 0.024540349 0.014020913 0.014608234 0.014867258 0.014915032 0.015760303 0.017901509 0.020706096 0.023441153 0.026396161 0.031745601 0.03841396 0.042687007 2.31%
Disease rarity 0.058466036 0.033404057 0.019141824 0.019481235 0.019543835 0.020651432 0.023457149 0.027132126 0.030715994 0.034588072 0.041597684 0.050335534 0.055934698 3.34%
Disease severity 0.053850296 0.055939809 0.032055685 0.017943243 0.018000901 0.019021056 0.021605269 0.024990116 0.028291047 0.031857435 0.038313656 0.046361676 0.051518801 3.38%
Adv.tech. 0.00615432 0.006393121 0.006660922 0.003728466 0.002057246 0.002173835 0.002469174 0.002856013 0.003233263 0.00364085 0.004378704 0.005298477 0.005887863 0.42%
Manufacturing technology 0.00307716 0.003196561 0.003330461 0.003389515 0.001870223 0.001086917 0.001234587 0.001428007 0.001616631 0.001820425 0.002189352 0.002649239 0.002943931 0.23%
Therapeutic alternative 0.106162012 0.110281337 0.114900898 0.116938252 0.117314019 0.068179368 0.042593244 0.049266229 0.055773779 0.062804658 0.075532637 0.091398732 0.101565636 8.56%
Sci. evid. Clin.eff 0.169243788 0.175810828 0.183175345 0.1864233 0.187022349 0.197621357 0.12345868 0.078540365 0.088914719 0.100123368 0.120414348 0.145708124 0.161916232 14.76%
Benefits from use of medicine (safety aspects) 0.13385645 0.139050382 0.144875045 0.147443882 0.147917676 0.156300528 0.177535622 0.112942343 0.07032346 0.079188482 0.095236803 0.11524188 0.12806102 12.68%
Cost effectiveness analysis 0.095391953 0.099093376 0.103244285 0.105074951 0.105412597 0.111386583 0.126519639 0.146341176 0.091119217 0.056433171 0.067869905 0.082126397 0.091261876 9.86%
Budget impact analysis 0.090776214 0.094298535 0.098248594 0.099990679 0.100311987 0.10599691 0.120397721 0.139260151 0.157654949 0.09764097 0.064585878 0.078152539 0.086845979 10.26%
Therapy cost 0.14154935 0.147041783 0.153201197 0.155917669 0.156418692 0.165283317 0.187738819 0.217151422 0.245834836 0.276824938 0.183109422 0.121864976 0.135420848 17.60%
HTA recommendations issued elsewhere 0.086160474 0.089503694 0.093252903 0.094906407 0.095211378 0.100607237 0.114275803 0.132179126 0.149638596 0.168502136 0.202650744 0.13487033 0.082430082 11.88%
Rationalization analysis 0.030771598 0.031965605 0.033304608 0.033895145 0.034004063 0.035931156 0.040812787 0.047206831 0.053442356 0.060179334 0.072375266 0.087578136 0.053526027 4.73%
SUM 1 1 1 1 1 1 1 1 1 1 1 1 1 100.00%
  1. Sci. evid. clin.eff Scientific evidence for clinical efficiency, Adv.tech. Advancement of technology